Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPX-601
- Development stage
- Discontinued
- Lead developer
- Bellicum Pharmaceuticals
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
BPX-601 is an investigational autologous chimeric antigen receptor T cell (CAR-T) therapy developed by Bellicum Pharmaceuticals for the treatment of solid tumors expressing prostate stem cell antigen (PSCA), including cancers of the prostate, pancreas, and stomach. The therapy uses a proprietary inducible MyD88/CD40 co-stimulatory domain (iMC), which can be pharmacologically activated by rimiducid to enhance T cell proliferation, persistence, and cytokine production. This design aims to improve CAR-T efficacy in solid tumors by overcoming immune inhibitory mechanisms such as PD-1 and TGF-beta. Unlike standard CARs that rely solely on antigen presence for activation and survival, BPX-601 allows external control over T-cell activity through rimiducid dosing[1][4][6]. Clinical trials demonstrated preliminary biologic activity but also revealed significant toxicities at higher doses; development was discontinued after phase 1/2 studies in advanced solid tumors[2][3][4].
- Other names
- GoCAR-T
02
Targets
PSCA (Prostate stem cell antigen)
Beyond the preview
Go deeper on BPX-601.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPX-601.